Thomas Povsic, MD
Cardiovascular Disease · Durham, NCNPI 1437233327
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,476 of the $23,554 with a category attached, or 65.7%. 6 manufacturers reported payments, led by CSL Behring at 33.8% of the total. Reporting peaked in 2019 at $15,175 and has fallen 87.7% since, to $1,860 in 2023.
Across 46 payments — averaging $512.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$8K
- Boehringer Ingelheim International GmbH$8K
- Eli Lilly$7K
- Astrazeneca AB$556
- Novo Nordisk$82
- Shockwave Medical, Inc$31
Across 165 payments — averaging $2104.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$322K
- E.r. Squibb & Sons, L.L.C.$19K
- Shockwave Medical, Inc$5K
- Boehringer Ingelheim International GmbH$300
What the payments were for
- Consulting fees$15,47666%
- Travel & lodging$6,23626%
- Food & beverage$1,8438%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 32 | $7,965 |
| Boehringer Ingelheim International GmbH | 10 | $7,710 |
| Eli Lilly | 1 | $7,210 |
| Astrazeneca AB | 1 | $556 |
| Novo Nordisk | 1 | $82 |
| Shockwave Medical, Inc | 1 | $31 |
How this compares
$23,554 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 29 | $23,238 |
| EliquisApixaban | 22 | $22,779 |
| XareltoRivaroxaban | 20 | $10,824 |
| Ezetimibe | 54 | $1,237 |
| Rosuvastatin Calcium | 78 | $1,087 |
| Metoprolol Succinate | 43 | $780 |
| Nitroglycerin PatchNitroglycerin | 12 | $382 |
| Pantoprazole Sodium | 15 | $343 |
| Carvedilol | 30 | $273 |
| Atorvastatin Calcium | 30 | $268 |
| ClopidogrelClopidogrel Bisulfate | 17 | $212 |
| Losartan Potassium | 17 | $193 |
| Nitroglycerin | 12 | $164 |
| Amlodipine Besylate | 15 | $100 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Robert MentzDurham$489K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Ankeet BhattDurham$258K
- Christopher GrangerDurham$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.